FDA Warning: Peanuts Detected in Certain Ritz Cracker Sandwiches Prompting Recall

The FDA has issued a risk warning and recall for certain Ritz cracker sandwiches due to undeclared peanuts, posing a serious allergy risk. Consumers should check labels carefully.
The U.S. Food and Drug Administration (FDA) has issued a risk warning concerning specific Ritz cracker sandwich products due to the potential presence of undeclared peanuts, a major allergen. This alert follows a voluntary recall announced by Mondelēz Global LLC on July 8, 2025. The recall affects several product sizes, including the Ritz Peanut Butter Cracker Sandwiches in 8-pack, 20-pack, and 224-case quantities, as well as the Ritz Filled Cracker Sandwich 20-count variety pack.
The recall was initiated after the discovery that packaging films used for wrapping individual peanut butter products may contain defects caused by a supplier error. While the outer cartons were correctly labeled to indicate the presence of peanuts, some individual packs were mislabeled as cheese sandwiches. Consumers with peanut allergies are strongly advised not to consume these products, which could cause serious or life-threatening allergic reactions such as hives, lip swelling, or anaphylaxis.
To date, no injuries or illnesses have been reported. The affected products have specific UPC codes and best-by dates ranging from November 2025 to January 2026. These products were sold nationwide at retail stores.
The allergen labeling error posed a serious health risk to individuals allergic to peanuts, making it crucial for consumers to check product labels carefully. Mondelēz Global LLC has assured that corrective actions are underway to prevent future issues.
For those who purchased these products and have peanut allergies, it is recommended to contact the company at 844-366-1171 for further assistance. Consumers are also encouraged to learn more about peanut allergies through reputable sources such as the American Academy of Allergy, Asthma & Immunology.
Source: https://medicalxpress.com/news/2025-07-ritz-fda-issues-due-undeclared.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Breakthrough in Steroid Receptor Research Could Lead to More Targeted Cancer Therapies
Innovative research uncovers the detailed structure of steroid hormone receptors, paving the way for targeted, side-effect-free cancer treatments. Discover how this breakthrough could revolutionize endocrine cancer therapy.
Advancements in Genetic Testing Enable More Women to Understand Hereditary Cancer Risks
Innovative genetic testing techniques are now enabling more women to determine their hereditary risk of breast and ovarian cancer, paving the way for personalized prevention and treatment strategies.
AI Innovation Enhances Blood Test Accuracy for Faster Cancer Monitoring
A new AI-driven blood test method, Fragle, enables faster, affordable, and highly accurate cancer monitoring by analyzing DNA fragment sizes, promising improved detection of relapse and treatment response.
Can Ozempic Help Lower Your Risk of Dementia?
Emerging research suggests that Ozempic's active ingredient, semaglutide, may help lower the risk of vascular dementia in people with type 2 diabetes through its anti-inflammatory and metabolic benefits.